Start › Nowotwór przerzutowy › Pensylwania › Pittsburgh
Badania kliniczne dla Nowotwór przerzutowy w mieście Pittsburgh, PA
31 badań dla Nowotwór przerzutowy szuka uczestników w ośrodkach w mieście Pittsburgh i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekrutacjaFaza 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- i 3 więcej
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
RekrutacjaFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RekrutacjaFaza 2/3
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
RekrutacjaFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekrutacjaFaza 1
- University of Pittsburgh Medical Center, Pittsburgh
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekrutacjaFaza 3
- AHN Allegheny General Hospital, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekrutacjaFaza 1/2
- Allegheny Health Network, Pittsburgh
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RekrutacjaFaza 1/2
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Clinical Study Site, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekrutacjaFaza 3
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
RekrutacjaFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekrutacjaFaza 1
- Allegheny General Hospital, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
RekrutacjaFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RekrutacjaFaza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RekrutacjaFaza 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RekrutacjaFaza 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RekrutacjaFaza 3
- AHN Cancer Center, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
RekrutacjaFaza 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
RekrutacjaFaza 2/3
- University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center, Pittsburgh
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
RekrutacjaFaza 1/2
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RekrutacjaFaza 2/3
- UPMC Hillman Cancer Center, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
RekrutacjaFaza 2
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 3
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekrutacjaFaza 2/3
- UPMC Hillman Cancer Center, Pittsburgh
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RekrutacjaFaza 1
- Hillman Cancer Center, Pittsburgh
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
RekrutacjaFaza 2
- Allegheny Health Network West Penn Hospital, Pittsburgh
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
RekrutacjaFaza 3
- University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
RekrutacjaFaza 1/2
- University of Pittsburgh, Pittsburgh
Badania dla Nowotwór przerzutowy w innych miastach
- Houston, TX104 badań
- New York City, NY93 badań
- Nashville, TN70 badań
- Boston, MA63 badań
- Los Angeles, CA57 badań
- St. Louis, MO54 badań
- Arlington, VA53 badań
- Philadelphia, PA46 badań
- Chicago, IL45 badań
- San Antonio, TX44 badań
- Washington, DC43 badań
- Dallas, TX42 badań
Inne badania w mieście Pittsburgh
- Niedrobnokomórkowy rak płuca48 badań
- Nowotwory (wszystkie typy)41 badań
- Rak piersi39 badań
- Rak jelita grubego i odbytnicy32 badań
- Czerniak31 badań
- Rak jajnika30 badań
- Rak endometrium23 badań
- Rak prostaty23 badań
- Rak płuc23 badań
- Rak płaskonabłonkowy głowy i szyi22 badań
- Udar22 badań
- Depresja22 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.